JianminXuMD

Pathology • Monrovia, CA

Dermatopathology, Hematopathology, Anatomic Pathology, Clinical Pathology

Business Owner of Xu Pathology Diagnostic Service Inc

Join to view full profile

Dr. Xu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Xu's full profile

Already have an account?

Office
605 E Huntington DR
Suite 209
Monrovia, CA 91016
Phone+1 626-599-6481

Summary

Dr. Jianmin Xu is a pathologist in California and is working in LabCorp. She received her medical degree from Southeast University Medical College and has been in practice 22 years. She specializes in dermatopathology, hematopathology, anatomic pathology, and clinical pathology. She has more than 100 publications and over 500 citings. She is CEO of Xu Pathology Diagnostic Service Inc.

Education & Training

University of Alabama Medical CenterFellowship, Dermatopathology, 2018 - 2019
University of California Davis HealthFellowship, Hematopathology, 2017 - 2018
Brookwood Baptist HealthResidency, Pathology-Anatomic and Clinical, 2013 - 2017
Southeast University Medical CollegeClass of 1995

Certifications & Licensure

CA State Medical License 2017 - 2026
NV State Medical License 2019 - 2025
AL State Medical License 2016 - 2021
PA State Medical License 2015 - 2016
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Dermatopathology
American Board of Pathology Hematopathology

Clinical Trials

The Protocol of Enhanced Recovery After Surgery in Colorectal Surgery Start of enrollment: 2006 Sep 01
Unknown status
Not Applicable
Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer Start of enrollment: 2008 Dec 01
Unknown status
Phase 3
Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Start of enrollment: 2008 Jan 01
Unknown status
Phase 4
Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles Start of enrollment: 2005 Jan 01
Completed
Phase 4
Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 4
Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Start of enrollment: 2008 Jan 01
Unknown status
Phase 4
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases Start of enrollment: 2012 Jun 01
Completed
Phase 3
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Start of enrollment: 2006 Sep 01
Unknown status
Phase 4
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM Start of enrollment: 2015 Oct 01
Suspended
Phase 3
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Start of enrollment: 2017 Apr 30
Recruiting
Phase 3
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Start of enrollment: 2017 Apr 30
Recruiting
Phase 4
Apatinib in the Treatment of Metastatic Colorectal Cancer Start of enrollment: 2018 Jan 01
Unknown status
Phase 2
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) Start of enrollment: 2016 Jan 01
Active, not recruiting
Phase 3
A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer Start of enrollment: 2019 Jul 17
Recruiting
Phase 2
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Start of enrollment: 2020 Sep 01
Not yet recruiting
Phase 3
The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients Start of enrollment: 2020 Aug 01
Not yet recruiting
Join now to see all

Publications & Presentations

PubMed

23 citations
Soil indigenous microorganisms weaken the synergy of Massilia sp. WF1 and Phanerochaete chrysosporium in phenanthrene biodegradation
Haiping Gu, Kang Yan, Qi You, Yuanzhi Chen, Yunhui Pan
The Science of the Total Environment. 2021-08-10
40 citations
Heavy metals in soil-vegetable system around E-waste site and the health risk assessment
Xingmei Liu, Shunbin Gu, Shiyan Yang, Jinsong Deng, Jianming Xu
The Science of the Total Environment. 2021-07-20
13 citations
Periphyton enhances arsenic release and methylation at the soil-water interface of paddy soils.
Ting Guo, Williamson Gustave, Haiying Lu, Yan He, Xianjin Tang
Journal of Hazardous Materials. 2021-05-05

Press Mentions

Robotic Surgery Shows Benefits vs. Laparoscopic Surgery for Middle, Low Rectal CancerJanuary 28th, 2022
Bevacizumab Boosts Liver Resection in RAS-Positive mCRCAugust 24th, 2020
A Novel Patient-Derived Organoids-Based Xenografts Model for Preclinical Drug Response Testing in Patients with Colorectal Liver MetastasesJune 12th, 2020
Join now to see all